arrow-right cart chevron-down chevron-left chevron-right chevron-up close menu minus play plus search share user email pinterest facebook instagram snapchat tumblr twitter vimeo youtube subscribe dogecoin dwolla forbrugsforeningen litecoin amazon_payments american_express bitcoin cirrus discover fancy interac jcb master paypal stripe visa diners_club dankort maestro trash

NEWS

CBDで体の免疫力を上げよう!


新型コロナウイルスとCBDの関係
CBDで体の免疫力を上げよう!

A month ago


いつもCBDTIMESをご利用いただき、ありがとうございます!
本日はCBDで体の免疫力を上げよう!というお話です。

CBDが体の免疫を上げ、コロナウイルスが人間の細胞に入っても増えない事が研究結果でわかりました。
研究者は、有望な動物データに基づいて、COVID-19を予防するためのCBDの臨床試験を推奨しています!



シカゴ大学の研究者チームは、大麻植物のカンナビジオール(CBD)が、ヒト細胞およびマウスにおけるSARS-CoV-2による感染を阻害できるという証拠を発見しました。
2022年1月20日の研究ではCBDは、てんかんの治療にFDA承認薬を服用している患者の医療記録の全国サンプルでSARS-CoV-2陽性検査と有意な情報を見つけました。
研究者たちは現在、CBDがCOVID-19の予防または早期治療として最終的に使用できるかどうかを決定するために臨床試験を行うべきであると述べています。
しかし、CBDのCOVID-19の遮断効果は、特定の状況で摂取された高純度のCBDを特別に処方された用量からのみもたらされると言われています。
この研究の結果は、効力と品質が異なるCBD添加物を含む市販の製品を摂取することでCOVID-19を予防できることを示唆しているわけではありません。

パンデミックが国や世界で続いており、ブレイクスルー感染がより一般的になるにつれて、科学者たちはコロナウイルスや新たな変異体に感染した人々、特にワクチンへのアクセスが不足している人々のための新しい治療法を探しています。

COVID-19の治療薬としてCBDをテストするというアイデアはたまたまでした。 「CBDには抗炎症作用があるので、免疫系が関与するCOVID-19の感染、いわゆる「サイトカインストーム」を止めることができると考えました。
驚くべきことに、CBDは肺細胞でのウイルスが増えるのを直接防ぎました」とMarsha氏は述べています。
Rosner、PhD、Charles B. Hugginsベンメイ癌研究部門の教授であり、この研究の上級著者です。
彼らは、特定の閾値濃度を超えると、CBDがウイルスの複製能力を阻害することを発見しました。さらなる調査により、CBDは他の2種類の細胞と、元の株に加えてSARS-CoV-2の3つの変異体でも同じ効果があることがわかりました。
CBDはSARS-CoV-2が細胞に侵入する能力に影響を与えませんでした。代わりに、CBDは感染サイクルの初期とウイルスがすでに細胞に感染してから6時間後の増殖をブロックするのに効果的でした。

すべてのウイルスと同様に、SARS-CoV-2は、その遺伝子発現機構を乗っ取って、それ自体とそのウイルスタンパク質のコピーをより多く生成することにより、宿主細胞に影響を与えます。この効果は、ウイルスが誘導する細胞RNAの変化を追跡することで観察できます。高濃度のCBDはウイルスRNAの発現をほぼ完全に根絶しました。まったく予想外の結果でした。
研究者らは、CBDがSARS-CoV-2複製をブロックするメカニズムには、宿主細胞のストレスの1つであるCBDの活性化と、抗ウイルス細胞タンパク質であるインターフェロンの生成が関与することを示しました。
研究者たちは、CBDが生きている動物のウイルス複製を防ぐことを示す科学的データを望んでいました。チームは、SARS-CoV-2に感染する前に、CBDによる前処理を1週間示し、マウスの肺と鼻腔の両方で感染を抑制しました。 「これらの結果は、ヒトにおけるCBDの臨床試験の主要なサポートを提供します」とRosnerは述べています。

CBDがSARS-CoV-2に最近曝露または感染した患者を治療する可能性は、COVID-19に対する最初の防衛線に先行していません。
これは、ワクチン接種を受け、屋内空間でのマスキングと社会的距離に関する既存の公衆衛生ガイドラインに従うことです。
しかし、公表された結果は、潜在的な新しい治療法を提供し、パンデミックが激化するにつれて、まだ何かが必要とされています。

「CBDがSARS-CoV-2感染の予防または抑制に本当に効果的かどうかを判断するには臨床試験が必要ですが、これは予防的治療としての可能性があると考えています」とRosner氏は述べています。

 https://www.uchicagomedicine.org/forefront/research-and-discoveries-articles/researchers-recommend-clinical-trials-for-cbd


An interdisciplinary team of researchers from the University of Chicago has found evidence that cannabidiol (CBD), a product of the cannabis plant, can inhibit infection by SARS-CoV-2 in human cells and in mice.

The study, published on January 20, 2022, in Science Advances, found CBD showed a significant negative association with SARS-CoV-2 positive tests in a national sample of medical records of patients taking the FDA-approved drug for treating epilepsy. The researchers now say that clinical trials should be done to determine whether CBD could eventually be used as a preventative or early treatment for COVID-19. They caution, however, that the COVID-blocking effects of CBD come only from a high purity, specially formulated dose taken in specific situations. The study’s findings do not suggest that consuming commercially available products with CBD additives that vary in potency and quality can prevent COVID-19.

Scientists have been looking for new therapies for people infected by the coronavirus and emerging variants, especially those who lack access to vaccines, as the pandemic continues across the country and world and as breakthrough infections become more common.

CBD: An unexpected avenue for fighting COVID-19

The idea to test CBD as a potential COVID-19 therapeutic was serendipitous. “CBD has anti-inflammatory effects, so we thought that maybe it would stop the second phase of COVID infection involving the immune system, the so-called ‘cytokine storm.’ Surprisingly, it directly inhibited viral replication in lung cells,” said Marsha Rosner, PhD, Charles B. Huggins Professor in the Ben May Department of Cancer Research and a senior author of the study.

To see this effect, the researchers first treated human lung cells with a non-toxic dose of CBD for two hours before exposing the cells to SARS-CoV-2 and monitoring them for the virus and the viral spike protein. They found that, above a certain threshold concentration, CBD inhibited the virus’ ability to replicate. Further investigation found that CBD had the same effect in two other types of cells and for three variants of SARS-CoV-2 in addition to the original strain.

CBD did not affect the ability of SARS-CoV-2 to enter the cell. Instead, CBD was effective at blocking replication early in the infection cycle and six hours after the virus had already infected the cell.

Like all viruses, SARS-CoV-2 affects the host cell by hijacking its gene expression machinery to produce more copies of itself and its viral proteins. This effect can be observed by tracking virus-induced changes in cellular RNAs. High concentrations of CBD almost completely eradicated the expression of viral RNAs. It was a completely unexpected result.

“We just wanted to know if CBD would affect the immune system,” Rosner said. “No one in their right mind would have ever thought that it blocked viral replication, but that’s what it did.”

The researchers showed that the mechanism by which CBD blocks SARS-CoV-2 replication involves CBD activation of one of the host cell stress responses and generation of interferons, an antiviral cell protein.

 

Real world data: Patients taking CBD test positive for COVID-19 at lower rates

The researchers wanted scientific data to show that CBD prevents viral replication in live animals. The team showed pretreatment with CBD for one week prior to infection with SARS-CoV-2 suppressed infection both in the lung and the nasal passages of mice. “These results provide major support for a clinical trial of CBD in humans,” said Rosner.

And the success of CBD wasn’t limited to the laboratory: An analysis of 1,212 patients from the National COVID Cohort Collaborative revealed that patients taking a medically prescribed oral solution of CBD for the treatment of epilepsy tested positive for COVID-19 at significantly lower rates than a sample of matched patients from similar demographic backgrounds who were not taking CBD.

The potential for CBD to treat patients recently exposed to or infected by SARS-CoV-2 does not precede the first lines of defense against COVID-19, which are to get vaccinated and follow existing public health guidelines for masking in indoor spaces and social distancing. But the published results offer a potential new therapeutic, something still needed as the pandemic rages on.

“A clinical trial is necessary to determine whether CBD is really effective at preventing or suppressing SARS-CoV-2 infection, but we think this may have potential as a prophylactic treatment,” said Rosner. “Maybe you’re in a hot spot or you think you might have been exposed or you’ve just tested positive — that’s where we think CBD might have an effect.”

 

Not your dispensary’s CBD

“Going to your corner bakery and buying some CBD muffins or gummy bears probably won’t do anything,” said Rosner. “The commercially available CBD powder we looked at, which was off the shelf and something you could order online, was sometimes surprisingly of high purity but also of inconsistent quality. It is also hard to get into an oral solution that can be absorbed without the special, FDA-approved formulation,” Rosner said.

While the study’s results are exciting, additional study is needed to determine the precise dosing of CBD that is effective at preventing SARS-CoV-2 infection in humans as well as its safety profile and any potential side effects.

“We are very eager to see some clinical trials on this subject get off the ground,” Rosner said. “Especially as we are seeing that the pandemic is still nowhere near the end — determining whether this generally safe, well-tolerated, and non-psychoactive cannabinoid might have anti-viral effects against COVID-19 is of critical importance.”

Rosner was also pleased that this research project was a case study in the power of scientific collaboration by bringing together a highly interdisciplinary group of researchers. Senior authors listed on the paper came from three different research universities and from departments as diverse as microbiology, molecular engineering, cancer biology and chemistry.

“This was truly a team-science effort, and that’s something that really excites me,” said Rosner. “From clinicians to David Meltzer’s group who did the patient analysis to virologists like Glenn Randall, and it goes on and on. This is the way science should be carried out.”

The study, “Cannabidiol Inhibits SARS-CoV-2 Replication through Induction of the Host ER Stress and Innate Immune Responses,” was supported by a BIG Vision grant from the University of Chicago, the National Institutes of Health (R01 GM121735, R01 CA184494, R01 AI137514, R01 AI127518, R01 AI134980, R01 CA219815, R35 GM119840, P30 CA014599), and the Harry B. and Leona M Helmsley Charitable Trust. Additional authors include Long Chi Nguyen, Dongbo Yang, Thomas J. Best, Nir Drayman, Adil Mohamed, Christopher Dann, Diane Silva, Lydia Robinson-Mailman, Andrea Valdespino, Letícia Stock, Eva Suárez, Krysten A. Jones, Saara-Anne Azizi, James Michael Millis, Bryan C. Dickinson, Savaş Tay, Scott A. Oakes, and David O. Meltzer of the University of Chicago; Vlad Nicolaescu, Haley Gula, and Glenn Randall of UChicago and Argonne National Laboratory; Divayasha Saxena, Jon D. Gabbard, Jennifer K. Demarco, William E. Severson, Charles D. Anderson, and Kenneth E. Palmer of the University of Louisville; Shao-Nong Chen, Takashi Ohtsuki, John Brent Friesen, and Guido F. Pauli of the University of Illinois at Chicago; and the National COVID Cohort Collaborative Consortium.

ショッピングカート